Close

Clinical Trials

Sorrento begin patient enrollment in phase 2 study of...

Sorrento Therapeutics, Inc. announced the start of enrollment in its Phase 2 efficacy study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSCâ„¢) for patients suffering...

NRx’s Zyesami lowers respiratory distress in Phase IIb/III Covid-19...

NRx Pharmaceuticals has reported additional data from Phase IIb/III clinical trial where its drug, Zyesami (aviptadil), offered a rise in blood oxygen within a day...

Curevac’s CV2CoV Demonstrates Improved Immune Response And Protection In...

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, and GSK announced the publication of preclinical...

Valneva Initiates Further Phase 3 Clinical Trial for its...

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced the...

AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine...

AzurRx BioPharma, Inc., a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, announced the completion of site initiation visits...

Valneva Announces Positive Phase 3 Pivotal Results for its...

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced positive...

Lilly and Incyte’s baricitinib reduced deaths among patients with...

Eli Lilly and Company and Incyte announced results from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study, patients with...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read